Shining Hope for Myotonic Dystrophy: A New Drug Discovery - Science View

Key Concepts

• Myotonic Dystrophy: A hereditary disease causing progressive muscle weakness, with no known cure or way to halt its progression.
• Genetic Abnormality: The underlying cause of myotonic dystrophy, specifically an excessive repetition of the CTG base sequence in genes, leading to abnormal RNA.
• Abnormal RNA: RNA with a hairpin-like shape due to repeated CTG sequences, which traps regulatory factors essential for bodily functions, particularly muscle function.
• Regulatory Factors: Proteins crucial for maintaining normal bodily functions that become trapped by abnormal RNA in myotonic dystrophy.
• Azithromycin: An existing antibiotic drug identified as a potential treatment for myotonic dystrophy by blocking the activity of abnormal RNA.
• Clinical Trials: A multi-stage process to test the safety and effectiveness of a new drug or treatment in humans.
• Placebo: An inactive substance used as a control in clinical trials to compare its effects against the actual drug.
• PPR Proteins: Proteins found in plants (specifically Arabidopsis thaliana) that have a strong binding affinity to RNA and can be engineered to target specific RNA sequences.
• Robot Suit: An assistive device that detects brain signals to aid in body movement, used by patients to help slow muscle decline.

Myotonic Dystrophy: A Battle Against an Incurable Disease

This video chronicles the journey of patients battling myotonic dystrophy, a hereditary disease characterized by progressive muscle weakness, and the dedicated research of Professor Masayuki Nakamori of Yamaguchi University, who is striving to find a treatment.

Patient Stories and Disease Overview

• Sato Mino: A patient with myotonic dystrophy, whose life has been significantly impacted by the disease. She previously held a key position at a supermarket and was active in a theater company, but her options became limited as her condition worsened. Her son also has the same diagnosis.
• Disease Impact: Myotonic dystrophy gradually weakens muscles in the limbs and face, increasing the risk of other serious conditions affecting organs like the heart, brain, and eyes.
• Prevalence: While exact numbers are difficult to ascertain due to undiagnosed cases, it's estimated that at least 10,000 people in Japan and over a million worldwide are affected.
• Genetic Basis: The disease stems from genetic abnormalities where a base sequence called CTG is repeated excessively. This leads to the formation of abnormally shaped RNA (CUG repeats) that traps essential regulatory factors, impairing muscle function and other bodily processes.

Professor Nakamori's Research: Repurposing Existing Drugs

Professor Nakamori's research focuses on finding a treatment for myotonic dystrophy, a condition for which no effective cure or progression-halting drug currently exists.

• Inspiration: Driven by the lack of treatment options he observed as a neurologist, Professor Nakamori dedicated himself to research while continuing his clinical work.
• Methodology: He investigated tens of thousands of existing drugs and compounds to identify potential candidates.
  1. Initial Selection: Drugs that could bind to RNA were selected (approximately 1,000).
  2. Safety Verification: The list was narrowed down to those with verified safety to a certain degree (around 200).
  3. Side Effect Filtering: Drugs without serious side effects and suitable for long-term use were identified, resulting in approximately 20 compounds.
• Discovery of Azithromycin: Professor Nakamori tested these 20 candidate substances on cells with myotonic dystrophy. He discovered that azithromycin, an antibiotic commonly used for infections like pneumonia, could block the activity of the abnormal RNA.
  • Evidence: Microscopic images showed a disappearance of red dots (indicating abnormal RNA) in cells treated with azithromycin compared to untreated cells.
  • Animal Studies: Experiments on mice with myotonic dystrophy demonstrated that administering azithromycin increased the percentage of normal RNA, confirming its therapeutic effect.
• Clinical Trials: Based on these findings, clinical trials were conducted at three hospitals, involving 30 patients. These trials were double-blind, meaning neither patients nor doctors knew who received azithromycin or a placebo.
  • Results: The trials showed a clear effect in many patients who received azithromycin, with significant improvements observed in normal RNA levels and other indicators.
• Timeline for Availability: Professor Nakamori aims to make azithromycin available to patients within 3 years, pending confirmatory trials to prove its safety and effectiveness.

Advancing Treatment: The Potential of PPR Proteins

While azithromycin offers hope, Professor Nakamori acknowledges it's not a perfect solution and is exploring more targeted approaches.

• Limitations of Azithromycin: The binding of azithromycin to abnormal RNA is described as relatively weak, suggesting room for improvement in selectivity and binding strength.
• Discovery of PPR Proteins: Research at Kyushu University identified PPR proteins, naturally occurring in plants like Arabidopsis thaliana, which bind strongly to RNA and regulate its activity.
  • Mechanism: The amino acid sequences of PPR proteins determine their RNA base binding specificity.
  • Application: A startup is applying this knowledge to develop new uses for PPR proteins.
• Engineering PPR Proteins: Researchers at the startup created modified Arabidopsis thaliana varieties with specific PPR protein functions switched off. They then extracted RNA and analyzed the relationship between PPR proteins and RNA to understand their binding structures. This allowed them to create PPR genes with desired sequences.
• Professor Nakamori's Collaboration: Professor Nakamori collaborated with Yusuke Yagi's team to create PPR genes that bind specifically to the CUG sequence of RNA causing myotonic dystrophy.
• Promising Results: When administered to mice with myotonic dystrophy, these engineered PPR proteins showed a significant increase in the percentage of normal RNA.
• Future Potential: This technology offers the ability to control RNA that causes illness and has the potential to treat other incurable diseases mediated by abnormal RNA, such as ALS.

Ongoing Support and Future Outlook

• Patient Support: Sato Mino continues her training with a robot suit that assists with body movement, aiming to slow the decline in her walking ability, and places her hope in Professor Nakamori's research.
• Professor Nakamori's Commitment: He expresses a lifelong dedication to ending patient suffering and hopes the PPR technology can help cure as many diseases as possible.
• Parallel Research: Research on azithromycin and PPR proteins will continue in parallel, with the aim of treating patients with azithromycin while awaiting the practical readiness of PPR-based treatments.

Conclusion

The video highlights a significant breakthrough in the fight against myotonic dystrophy, moving from a state of no treatment to promising therapeutic options. Professor Nakamori's dedication, coupled with innovative research into repurposing existing drugs and engineering novel plant-based proteins, offers a tangible ray of hope for patients and their families. The ongoing research signifies a potential paradigm shift in treating genetic diseases at their root cause.